Mizuho Securities analyst Ann Hynes maintained a Hold rating on McKesson (MCK – Research Report) on February 1 and set a price target of $376.00. The company’s shares closed yesterday at $366.48.
According to TipRanks, Hynes is a 5-star analyst with an average return of 9.3% and a 63.34% success rate. Hynes covers the Healthcare sector, focusing on stocks such as HCA Healthcare, Humana, and Cardinal Health.
Currently, the analyst consensus on McKesson is a Strong Buy with an average price target of $427.00.
See today’s best-performing stocks on TipRanks >>
MCK market cap is currently $53.69B and has a P/E ratio of 26.29.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MCK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incorporated in 1833, Texas-based McKesson Corp. provides pharmaceuticals, health information technology, medical supplies, and care management tools. The company operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions.
Read More on MCK: